Showing 653 results

Filters Content type: News, Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Editor's pick
Achillion press release
14 January 2014
New & experimental hepatitis C treatment

Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

Editor's pick
Vertex press release
9 January 2014
New & experimental hepatitis C treatment

Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Editor's pick
Bristol-Myers Squibb press release
8 January 2014
New & experimental hepatitis C treatment

$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Editor's pick
NPR (blog)
6 January 2014
Hepatitis C treatment

Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Editor's pick
Seeking Alpha
3 January 2014
New & experimental hepatitis C treatment

Stellar hepatitis C data puts Gilead farther ahead of pack

Editor's pick
Reuters
24 December 2013
Access to healthcare

Life-saving hepatitis C drug approved, but cost is high

Editor's pick
IRIN Plus News
24 December 2013
Access to healthcare

Egyptians hold their breath as new Hepatitis C drugs promise cure

Editor's pick
Ahram Online
24 December 2013
New & experimental hepatitis C treatment

Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks

News
18 December 2013
New & experimental hepatitis C treatment

Gilead to seek okay for combo hepatitis C pill in first quarter

Editor's pick
Reuters
18 December 2013
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Editor's pick
Gilead press release
18 December 2013
Access to healthcare

How patent rules could keep new hepatitis C drug from saving 'millions of lives'

Editor's pick
Global Post
18 December 2013
New & experimental hepatitis C treatment

An interview with Professor Jean-Michel Pawlotsky on how the treatment of HCV infection will change in the near future

Editor's pick
Hepatitis B & C Public Policy Association
17 December 2013
New & experimental hepatitis C treatment

Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

Editor's pick
Reuters
16 December 2013
New & experimental hepatitis C treatment

Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large

Editor's pick
Forbes
11 December 2013
New & experimental hepatitis C treatment

Express Scripts Pushes Price Competition for Gilead Drug

Editor's pick
Bloomberg
11 December 2013
New & experimental hepatitis C treatment

AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

Editor's pick
AbbVie press release
10 December 2013
Pharmaceutical industry

Activists Condemn Gilead for Exorbitant Price of Their New Hepatitis C Drug

Editor's pick
Fair Pricing Coalition / The Body
10 December 2013
New & experimental hepatitis C treatment

Beyond the Hype: What Sofosbuvir Means—and Doesn’t—for Global Hepatitis C Treatment

Editor's pick
Open Society Foundation
10 December 2013
New & experimental hepatitis C treatment

US FDA approves Gilead's $1000-a-day hepatitis C pill

Editor's pick
Reuters
8 December 2013
New & experimental hepatitis C treatment

FDA approves Sovaldi for chronic hepatitis C

Editor's pick
US FDA
8 December 2013
New & experimental hepatitis C treatment

Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?

Editor's pick
Medscape (requires registration)
4 December 2013
Pharmaceutical industry

Fair Pricing Coalition Disappointed by the High Price of New Janssen Hepatitis C Drug Olysio (simeprevir)

Editor's pick
Fair Pricing Coalition
29 November 2013
New & experimental hepatitis C treatment

Gilead responds over India patent pressure on HCV drug

Editor's pick
PharmaTimes
27 November 2013